FI3821891T3 - FK506:n käyttö pulmonaarisen valtimohypertension hoidossa - Google Patents
FK506:n käyttö pulmonaarisen valtimohypertension hoidossa Download PDFInfo
- Publication number
- FI3821891T3 FI3821891T3 FIEP20211109.2T FI20211109T FI3821891T3 FI 3821891 T3 FI3821891 T3 FI 3821891T3 FI 20211109 T FI20211109 T FI 20211109T FI 3821891 T3 FI3821891 T3 FI 3821891T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- arterial hypertension
- subject
- pulmonary arterial
- use according
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 claims 9
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 claims 4
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 claims 4
- 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 102000012085 Endoglin Human genes 0.000 claims 2
- 108010036395 Endoglin Proteins 0.000 claims 2
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481317P | 2011-05-02 | 2011-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3821891T3 true FI3821891T3 (fi) | 2023-08-24 |
Family
ID=47108011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20211109.2T FI3821891T3 (fi) | 2011-05-02 | 2012-04-30 | FK506:n käyttö pulmonaarisen valtimohypertension hoidossa |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US9474745B2 (enExample) |
| EP (3) | EP3821891B1 (enExample) |
| JP (1) | JP6177765B2 (enExample) |
| AU (2) | AU2012250974B9 (enExample) |
| CA (1) | CA2834368C (enExample) |
| CY (1) | CY1123900T1 (enExample) |
| DK (2) | DK2704711T3 (enExample) |
| ES (2) | ES2856173T3 (enExample) |
| FI (1) | FI3821891T3 (enExample) |
| HR (1) | HRP20210245T1 (enExample) |
| HU (1) | HUE053229T2 (enExample) |
| LT (1) | LT2704711T (enExample) |
| PL (1) | PL2704711T3 (enExample) |
| PT (2) | PT2704711T (enExample) |
| RS (1) | RS61480B1 (enExample) |
| SI (1) | SI2704711T1 (enExample) |
| SM (1) | SMT202100085T1 (enExample) |
| WO (1) | WO2012151153A1 (enExample) |
| ZA (1) | ZA201307905B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017009110A (es) * | 2015-01-13 | 2017-11-09 | Vivus Inc | Terapia de combinacion para hipertension pulmonar. |
| EP3294294A4 (en) * | 2015-05-08 | 2019-01-02 | Vivus, Inc. | Compositions and methods for the treatment or prevention of pulmonary hypertension |
| CN105062976B (zh) * | 2015-08-05 | 2018-05-11 | 中国医学科学院基础医学研究所 | 肺动脉高压治疗药物的干细胞筛选模型及应用 |
| ES2683921B1 (es) * | 2017-03-28 | 2019-04-22 | Univ Vigo | Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar |
| JP2020520906A (ja) * | 2017-05-19 | 2020-07-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 肺高血圧症の治療のためのエンザスタウリン及び脆弱性ヒスチジン三連構造（ｆｈｉｔ）増加剤 |
| EP3773571A1 (en) * | 2018-03-28 | 2021-02-17 | Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin | Prevention or treatment of chronic organ injury |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| US20050119330A1 (en) * | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
| FR2936060B1 (fr) * | 2008-09-17 | 2010-11-19 | Assist Publ Hopitaux De Paris | Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire. |
| MX2011004284A (es) * | 2008-10-22 | 2011-06-21 | Sam Amer & Co Inc | Metodo para tratar la hipertension arterial pulmonar. |
-
2012
- 2012-04-30 JP JP2014509338A patent/JP6177765B2/ja active Active
- 2012-04-30 PL PL12779354T patent/PL2704711T3/pl unknown
- 2012-04-30 EP EP20211109.2A patent/EP3821891B1/en active Active
- 2012-04-30 HR HRP20210245TT patent/HRP20210245T1/hr unknown
- 2012-04-30 DK DK12779354.5T patent/DK2704711T3/da active
- 2012-04-30 ES ES12779354T patent/ES2856173T3/es active Active
- 2012-04-30 CA CA2834368A patent/CA2834368C/en active Active
- 2012-04-30 DK DK20211109.2T patent/DK3821891T3/da active
- 2012-04-30 LT LTEP12779354.5T patent/LT2704711T/lt unknown
- 2012-04-30 RS RS20210239A patent/RS61480B1/sr unknown
- 2012-04-30 PT PT127793545T patent/PT2704711T/pt unknown
- 2012-04-30 SI SI201231881T patent/SI2704711T1/sl unknown
- 2012-04-30 HU HUE12779354A patent/HUE053229T2/hu unknown
- 2012-04-30 FI FIEP20211109.2T patent/FI3821891T3/fi active
- 2012-04-30 EP EP12779354.5A patent/EP2704711B1/en active Active
- 2012-04-30 PT PT202111092T patent/PT3821891T/pt unknown
- 2012-04-30 SM SM20210085T patent/SMT202100085T1/it unknown
- 2012-04-30 ES ES20211109T patent/ES2954905T3/es active Active
- 2012-04-30 US US14/113,375 patent/US9474745B2/en active Active
- 2012-04-30 EP EP23177834.1A patent/EP4279130A3/en not_active Withdrawn
- 2012-04-30 AU AU2012250974A patent/AU2012250974B9/en active Active
- 2012-04-30 WO PCT/US2012/035793 patent/WO2012151153A1/en not_active Ceased
-
2013
- 2013-10-23 ZA ZA2013/07905A patent/ZA201307905B/en unknown
-
2016
- 2016-09-21 US US15/271,794 patent/US20170007585A1/en not_active Abandoned
-
2017
- 2017-08-03 AU AU2017210583A patent/AU2017210583B2/en active Active
- 2017-10-12 US US15/782,153 patent/US20180185340A1/en not_active Abandoned
-
2018
- 2018-11-21 US US16/198,242 patent/US20190091208A1/en not_active Abandoned
-
2020
- 2020-07-29 US US16/941,778 patent/US20220184042A1/en not_active Abandoned
-
2021
- 2021-02-23 CY CY20211100151T patent/CY1123900T1/el unknown
-
2023
- 2023-01-06 US US18/151,028 patent/US20230404982A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3821891T3 (fi) | FK506:n käyttö pulmonaarisen valtimohypertension hoidossa | |
| WO2010068810A3 (en) | Certain substituted amides, method of making, and method of use thereof | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2013527189A5 (enExample) | ||
| MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
| WO2011055944A3 (en) | Methods for treating fibromyalgia syndrome | |
| JP2010248252A5 (enExample) | ||
| JP2012092110A5 (enExample) | ||
| EA201100756A1 (ru) | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенным профилем безопасности по сравнению со стандартным лечением варфарином | |
| WO2012094598A3 (en) | Pharmaceutical compositions of iron for oral administration | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| UA108072C2 (uk) | Засіб для профілактики і лікування високопатогенних інфекційних захворювань | |
| FI3119911T3 (fi) | Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa | |
| JP2009537554A5 (enExample) | ||
| JP2014507474A5 (enExample) | ||
| BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" | |
| RU2015151175A (ru) | Способы улучшения липидных профилей с применением атрасентана | |
| JP2014513121A5 (enExample) | ||
| JP2014522817A5 (enExample) | ||
| WO2010012459A3 (en) | A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| EA201590474A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ | |
| WO2012142575A3 (en) | Monomeric trioxane amide sulfur compounds |